Recap: Amgen Q2 Earnings

Shares of Amgen AMGN were flat in after-market trading after the company reported Q2 results.

Quarterly Results

Earnings per share rose 7.05% year over year to $4.25, which beat the estimate of $3.84.

Revenue of $6,206,000,000 rose by 5.71% year over year, which beat the estimate of $6,180,000,000.

Outlook

Earnings guidance hasn't been issued by the company for now.

Amgen hasn't issued any revenue guidance for the time being.

Conference Call Details

Date: Jul 28, 2020

Time: 05:00 PM

ET Webcast URL: https://edge.media-server.com/mmc/p/zu6j6vvu

Technicals

52-week high: $264.97

52-week low: $173.12

Price action over last quarter: Up 12.56%

Company Description

Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and received approval for bone-strengthening drug Prolia/Xgeva in 2010. Amgen's acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Nexavar and Kyprolis. Recent launches include Repatha (cholesterol-lowering) and Aimovig (migraine).